Home About us Services Contact
 

News

Collectively, the data show TG Therapeutics heavily reliant on BRIUMVI’s U.S. sales, a strategic pivot toward subcutaneous delivery, and an emerging but still nascent cell‑therapy pipeline. The company’s financials, valuation metrics, and forthcoming product launches continue to shape investor expectations and market valuation.
Full article
10/03/2026 | TG Therapeutics, Inc.
Revenue and earnings forecasts diverge. Some projections anticipate $1.2 billion in revenue and $469 million in earnings by 2028, while others assume $1.0 billion in revenue and $344.7 million in earnings. These disparities highlight uncertainty around payer pushback, competition, and the pace of azer‑cel progress.
Full article
10/03/2026 | TG Therapeutics, Inc.
Capital‑market sentiment reflects this strategic focus. Bank of America reaffirmed a Sell rating with a $15 price target, citing a 49 % downside from current levels. Despite a 24 % decline in total shareholder return, the three‑year return has more than doubled, and analysts maintain an intrinsic value of $132.02 per share against a market price of...
Full article
10/03/2026 | TG Therapeutics, Inc.
The company’s 2025 earnings release underscored the centrality of BRIUMVI, noting the drug’s proven efficacy in reducing relapse and MRI activity in highly active relapsing multiple sclerosis. A clinical milestone for azercabtagene zapreleucel (azer‑cel) in progressive MS, which generated a $7.5 million payment from Precision BioSciences, marked th...
Full article
10/03/2026 | TG Therapeutics, Inc.
BRIUMVI sales dominated TG Therapeutics’ 2025 performance, with $594 million in U.S. net product sales contributing to total global revenue of $616 million. Net income for the year was $447.2 million, driven by $23 million in Q4 earnings and operating expenses of $328 million. TG projects 2026 operating costs to rise to $350 million, plus an additi...
Full article
10/03/2026 | TG Therapeutics, Inc.
Financially, Cricut reported platform gross margins of roughly 80% for four consecutive years and highlighted consistent subscriber growth. Its cash allocation framework prioritizes organic investment, opportunistic mergers and acquisitions, and shareholder returns. The company reaffirmed its commitment to shareholder value through ongoing share bu...
Full article
10/03/2026 | Cricut, Inc.
In addition to hardware, Cricut launched a Direct‑to‑Film (DTF) service, allowing customers to upload images and receive full‑color prints for transfer onto various substrates. This represents an early move to monetize the platform beyond cutting machines, leveraging existing infrastructure to expand product offerings.
Full article
10/03/2026 | Cricut, Inc.
Cricut presented its “bundle‑first” strategy at the Morgan Stanley TMT Conference, emphasizing a shift toward simplified, affordable entry points for new users. The company announced next‑generation machines that cut production costs while adding capability, and it unveiled “Guided Flows” starter bundles that include all components needed to comple...
Full article
10/03/2026 | Cricut, Inc.
Seven Hills Realty Trust (Nasdaq: SEVN) closed two new first‑mortgage loan investments totaling $37.0 million. The loans are secured by a retail center and a hospitality property: Town Center Plaza in Palm Desert, California—anchored by nationally recognized retailers—and SpringHill Suites Scottsdale in Arizona, a newly constructed Marriott‑branded...
Full article
10/03/2026 | Seven Hills Realty Trust
Market valuation metrics indicate a conservative outlook: Vodafone trades at 0.88x sales and 0.54x book value, with a forward price‑earnings ratio of 15.58, near the lower end of the telecom sector. Analysts maintain a “Hold” consensus, with a mean target price of $11.49.
Full article
09/03/2026 | Vodafone Group Public Limited Company